Tumour necrosis factor α and nuclear factor κB inhibit transcription of human TFF3 encoding a gastrointestinal healing peptide

Gut

Volumn 52, Issue 9, 2003, Pages 1297-1303

  Loncar, M B ^a   Al Azzeh, E D ^a   Sommer, P S M ^b   Marinovic, M ^c   Schmehl, K ^c   Kruschewski, M ^d   Blin, N ^a   Stohwasser, R ^c   Gott P ^a   Kayademir, T ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b FEDERAL UNIVERSITY OF RIO GRANDE DO NORTE   (Brazil)

^c GERMAN INSTITUTE OF HUMAN NUTRITION   (Germany)

^d FREIE UNIVERSITÄT BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MUCIN; TREFOIL PEPTIDE; TREFOIL PEPTIDE 1; TREFOIL PEPTIDE 2; TREFOIL PEPTIDE 3; TRINITROBENZENESULFONIC ACID; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLITIS; CONTROLLED STUDY; ENTERITIS; GENE EXPRESSION; GENETIC ANALYSIS; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; NONHUMAN; PATHOGENESIS; POLYMERASE CHAIN REACTION; RAT; REPORTER GENE; TUMOR CELL LINE; ULCER; WOUND HEALING;

ANIMALS; COLITIS; DOWN-REGULATION; GENE EXPRESSION REGULATION; GENES, REPORTER; HT29 CELLS; HUMANS; LUCIFERASES; MODELS, ANIMAL; NEUROPEPTIDES; NF-KAPPA B; POLYMERASE CHAIN REACTION; RATS; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0041885346     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.52.9.1297     Document Type: Article

References (61)

1. Beutler B, Cerami A. Tumor necrosis, cachexia, shock, and inflammation: a common mediator. Annu Rev Biochem 1988;57:505-18.
2. Armstrong AM, Foulkes R, Jennings G, et al. Tumour necrosis factor inhibitors reduce the acute-phase response in hapten-induced colitis. Br J Surg 2001;88:235-40.
3. Baert FJ, Rutgeerts PJ. Medical therapies for ulcerative colitis and Crohn's disease. Curr Gastroenterol Rep 2000;2:446-50.
4. Ghosh S, May MJ, Kopp EB. NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. Annu Rev Immunol 1998;16:225-60.
5. Schmid RM, Adler G. NF-kB/Rel/IkB: Implications in gastrointestinal diseases. Gastroenterology 2000;118:1208-28.
6. Baldwin AS.The NFκb and IkB proteins: New discoveries and Insights Annu Rev Immunol 1996;14:649-81.
7. Neurath MF, Pettersson S, Zum Büschenfelde, et al. Local administration of antisense phosphorothioate oligonucleotides to the p65 subunit of NF-kappaB abrogates established experimental colitis in mice. Nat Med 1996;2:998-1004.
8. Wahl C, Liptay S, Adler G, et al. Sulfasalazine: a potent and specific inhibitor of nuclear factor kappa B. J Clin Invest 1998;101:1163-74.
9. Fontaine V, van der Meijden E, de Graaf J, et al. A functional NF-kappaB binding site in the human papillomavirus type 16 long control region. Virology 2000;272:40-9.
10. Wissink S, van Heerde EC, Schmitz ML, et al. Distinct domains of the ReIA NF-kappaB subunit are required for negative cross-talk and direct interaction with the glucocorticoid receptor. J Biol Chem 1997;272:22278-84.
11. Supakar PC, Jung MH, Song CS, et al. Nuclear factor kappa B functions as a negative regulator for the rat androgen receptor gene and NF-kappa B activity increases during the age- dependent desensitization of the liver. J Biol Chem 1995;270:837-42.
12. Murakami S, Lefebvre V, de Crombrugghe B. Potent inhibition af the master chondrgenic factor Sox9 gene by interleukin-1 and tumor necrosis factor-alpha. J Biol Chem 2000;275:3687-92.
13. Podolsky DK, Lynch Devaney K, Stow JL, et al. Identification of human intestinal trefoil factor. Goblet cell- specific expression of a peptide targeted for apical secretion (published erratum appears in J Biol Chem 1993;268:12230). J Biol Chem 1993;268:6694-702.
14. Hauser F, Poulsom R, Chinery R, et al. hP1.B, a human P-domain peptide homologous with rat intestinal trefoil factor, is expressed also in the ulcer-associated cell lineage and the uterus. Proc Natl Acad Sci U S A 1993;90:6961-5.
15. Rio MC, Bellocq JP, Daniel JY, et al. Breast cancer-associated pS2 protein: synthesis and secretion by normal stomach mucosa. Science 1988;241:705-8.
16. Tomasetto C, Rio MC, Gautier C, et al. hSP, the domain-duplicated homolog of pS2 protein, is co- expressed with pS2 in stomach but not in breast carcinoma. EMBO J 1990;9:407-14.
17. Podolsky DK. Mechanisms of regulatory peptide action in the gastrointestinal tract: trefoil peptides. J Gastroenterol 2000;35(suppl 12):69-74.
18. Thim L. Trefoil peptides: from structure to function. Cell Mol Life Sci 1997;53:888-903.
19. Babyatsky MW, DeBeaumont M, Thim L, et al. Oral trefoil peptides protect against ethanol- and indomethacin- induced gastric injury in rats. Gastroenterology 1996;110:489-97.
20. Tran CP, Cook GA, Yeomans ND, et al. Trefoil peptide TFF2 (spasmolytic polypeptide) potently accelerates healing and reduces inflammation in a rat model of colitis. Gut 1999;44:636-42.
21. Toupin DR, Kinoshita K, Podolsky DK. Intestinal trefoil factor confers colonic epithelial resistance to apoptosis. Proc Natl Acad Sci U S A 2000;97:799-804.
22. Playford RJ, Marchbank T, Goodlad RA, et al. Transgenic mice that overexpress the human trefoil peptide pS2 have an increased resistance to intestinal damage. Proc Natl Acad Sci U S A 1996;93:2137-42.
23. Marchbank T, Cox HM, Goodlad RA, et al. Effect of ectopic expression of rat trefoil factor family 3 (rTFF3, intestinal trefoil factor) in the jeunum of transgenic mice. J Biol Chem 2001;26:24008-96.
24. Lefebvre O, Chenard MP, Masson R, et al. Gastric mucosa abnormalities and tumorigenesis in mice lacking the pS2 trefoil protein. Science 1996;274:259-62.
25. Mashimo H, Wu DC, Podolsky DK, et al. Impaired defense of intestinal mucosa in mice lacking intestinal trefoil factor. Science 1996;274:262-5.
26. Morris GP, Beck PL, Herridge MS, et al. Hapten-induced model of chronic inflammation and ulceration in the rat colon. Gastroenterology 1989;96:795-803.
27. Schmehl K, Florian S, Jacobasch G, et al. Deficiency of epithelial basement membrane laminin in ulcerative colitis affected human colonic mucosa. Int J Colorectal Dis 2000;15:39-48.
28. Beck S, Sommer P, Blin N, et al. 5′-flanking motifs control cell specific expression of trefoil factor genes (TFF). Int J Mol Med 1998;2:353-61.
29. Schmittgen TD, Zakrajsek BA Effect of experimental treatment on housekeeping gene expression: validation by real-time, quantitative RT-PCR. J Biochem Biophys Methods 2000;46:69-81.
30. Bours V, Burd PR, Brown K, et al. A novel mitogen-inducible gene product related to p50/p105-NF-kappa B participates in transactivation through a kappa B site. Mol Cell Biol 1992;12:685-95.
31. Desbarats L, Gaubatz S, Eilers M. Discrimination between different E-box-binding proteins at an endogenous target gene of c-myc. Genes Dev 1996;10:447-60.
32. Henkel T, Zabel U, van Zee K, et al. Intramolecular masking of the nuclear location signal and dimerization domain in the precursor for the p50 NF-kappa B subunit. Cell 1992;68:1121-33.
33. Dos Santos Silva E, Ulrich M, Döring G, et al. Trefoil factor family-domain peptides in the human respiratory tract. J Pathol 2000;190:133-42.
34. Jobin C, Sartor RB. The IkappaB/NF-kappaB system: a key determinant of mucosal inflammation and protection. Am J Physiol Cell Physiol 2000;278:C451-62.
35. Kaiser GC, Yan F, Polk DB. Mesalamine blocks tumor necrosis factor growth inhibition and nuclear factor kappa B activation in mouse colonocytes. Gastroenterology 1999;116:602-9.
36. Segain JP, Raingeard dIB, Bourreille A, et al. Butyrate inhibits inflammatory responses through NFkappaB inhibition: implications for Crohn's disease. Gut 2000;47:397-403.
37. Otto WR, Patel K. Trefoil factor family (TFF)-domain peptides in the mouse: embryonic gastrointestinal expression and wounding response. Anat Embryol 1999;199:499-508.
38. Xian CJ, Howarth GS, Mardell CE, et al. Temporal changes in TFF3 expression and jejunal morphology during methotrexate-induced damage and repair. Am J Physiol 1999;277:G785-95.
39. Kinoshita K, Taupin DR, Itoh H, et al. Distinct pathways of cell migration and antiapoptotic response to epithelial injury: structure-function analysis of human intestinal trefoil factor. Mol Cell Biol 2000;20:4680-90.
40. Playford RJ, Marchbank T, Chinery R, et al. Human spasmolytic polypeptide is a cytoprotective agent that stimulates cell migration. Gastroenterology 1995;108:108-16.
41. Kindon H, Pothoulakis C, Thim L, et al. Trefoil peptide protection of intestinal epithelial barrier function: cooperative interaction with mucin glycoprotein. Gastroenterology 1995;109:516-23.
42. Dossinger V, Kayademir T, Blin N, et al. Down-regulation of TFF Expression in Gastrointestinal Cell Lines by Cytokines and Nuclear Factors. Cell Physiol Biochem 2002;12:197-206.
43. Perkins ND. Achieving Transcriptional Specificity with NF-κB. Int J Biochem Cell Biol 1997;29:1433-48.
44. Mercurio F, Manning AM. NF-κB as primary regulator of the stress response. Oncogene 1999;18:6163-71.
45. LeClair KP, Blanar MA, Sharp PA. The p50 subunit of NF-kappa B associates with the NF-IL6 transcription factor. Proc Natl Acad Sci U S A 1992;89:8145-9.
46. Stein B, Cogswell PC, Baldwin AS Jr. Functional and physical associations between NF- kappa B and C/EBP family members: a Rel domain-bZIP interaction. Mol Cell Biol 1993;13:3964-74.
47. Boyd KE, Wells J, Gutman J, et al. c-Myc target gene specificity is determined by a post- DNA-binding mechanism. Proc Natl Acad Sci U S A 1998;95:13887-92.
48. Li J, Peet GW, Balzarano D, et al. Novel NEMO/IκB Kinase and NF-κB Target Genes at the Pre-B to Immature B Cell Transition. J Biol Chem 2001;276:18579-90.
49. Xiang Li, Massa PM, Adedayo H, et al. IKKα, IKKβ, and NEMO/IKKγ are each required for the NF-κB-mediated inflammatory response program. J Biol Chem 2002;277:45129-40.
50. Itoh H, Tomita M, Uchino H, et al. cDNA cloning of rat pS2 peptide and expression of trefoil peptides in acetic acid-induced colitis. Biochem J 1996;318:939-44.
51. Hoffmann W, Jagla W, Wiede A. moleculare medicine of TFF-peptides: From gut to brain. Histol Histopathol 2001;16:319-34.
52. Wright NA, Poulsom R, Stamp G, et al. Trefoil peptide gene expression in gastrointestinal epithelial cells in inflammatory bowel disease. Scand J Gastroenterol Suppl 1992;193:76-82.
53. Poulsom R, Chinery R, Sarraf C, et al. Trefoil peptide gene expression in small intestinal Crohn's disease and dietary adaptation. J Clin Gastroenterol 1993;17(suppl 1):S78-91.
54. Ahnen DJ, Poulsom R, Stamp GW, et al. The ulceration-associated cell lineage (UACL) reiterates the Brunner's gland differentiation programme but acquires the proliferative organization of the gastric gland. J Pathol 1994;173:317-26.
55. Khulusi S, Hanby AM, Marrero JM, et al. Expression of trefoil peptides pS2 and human spasmolytic polypeptide in gastric metaplasia at the margin of duodenal ulcers. Gut 1995;37:205-9.
56. Alison MR, Chinery R, Poulsom R, et al. Experimental ulceration leads to sequential expression of spasmolytic polypeptide, intestinal trefoil factor, epidermal growth factor and transforming growth factor alpha mRNAs in rat stomach. J Pathol 1995;175:405-14.
57. Lüdeking A, Fegert P, Blin N, et al. Osmotic changes and ethanol modify TFF gene expression in gastrointestinal cell lines. FEBS Lett 1998;439:180-4.
58. Beck S, Sommer P, Dos Santos Silva E, et al. Hepatocyte nuclear factor 3 (winged helix domain) activates trefoil factor gene TFF1 through a binding motif adjacent to the TATAA box. DNA Cell Biol 1999;18:157-64.
59. Al-azzeh E, Fegert P, Blin N, et al. Transcription factor GATA-6 activates expression of gastroprotective trefoil genes TFF1 and TFF2. Biochim Biophys Acta 2000;1490:324-32.
60. Ciacci C, Di Vizio D, Seth R, et al. Selective reduction of intestinal trefoil factor in untreated coeliac disease. Clin Exp Immunol 2002;130:526-31.
61. Rio MC, Chenard MP, Wolf C, et al. Induction of pS2 and hSP genes as markers of mucosal ulceration of the digestive tract. Gastroenterology 1991;100:375-9.